Sign up to save your podcasts
Or
Share Phase 2 UNITY-NHL Study Regarding Umbralisib
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Phase 2 UNITY-NHL Study Regarding Umbralisib
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
View all episodes
By Peter Ciszewski, CheckRare
5
33 ratings
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.